Physician profile
Laura Holtz
NPI 1992533178
$1,498.79
in general payments reported to CMS, 2019-2025
10 companies · $714 in 2025
The $714 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $784 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.80 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $486.30 | 2024-2025 | Alden Scleral Zenlens, Zenlens, Vyzulta |
| Alcon Vision LLC | $257.23 | 2024-2025 | Clareon |
| Dompe US, INC. | $207.37 | 2024-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $187.82 | 2024-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $156.85 | 2024-2025 | Xdemvy |
| Rayner Intraocular Lenses Limited | $86.24 | 2024 | Rayone Spheric, Rayner Cataract Set 1, Rayone Emv |
| Sun Pharmaceutical Industries INC. | $42.39 | 2025 | |
| Amgen INC. | $42.01 | 2024-2025 | Tepezza |
| Glaukos Corporation | $19.40 | 2025 | Idosetr |
| Sight Sciences, INC. | $13.18 | 2024 | Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Holtz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.